[Federal Register Volume 72, Number 133 (Thursday, July 12, 2007)]
[Notices]
[Pages 38086-38087]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E7-13560]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Antiviral Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Antiviral Drugs Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on September 5, 2007, from 
8 a.m. to 4 p.m. and on September 6, 2007, from 9 a.m. to 1 p.m.
    Location: On September 5, 2007, the committee will meet at the 
Hilton Washington DC/Silver Spring, The Ballrooms, 8727 Colesville Rd., 
Silver Spring, MD. The hotel telephone number is 301-589-5200. On 
September 6, 2007, the committee will meet in closed session at FDA, 
White Oak Headquarters, rm. 2046, 10903 New Hampshire Ave., Silver 
Spring, MD.
    Contact Person: Cicely Reese, Center for Drug Evaluation and 
Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for 
express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 
301-827-7001, FAX: 301-827-6776, e-mail: [email protected], or 
FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 
in the Washington, DC area), code 3014512531. Please call the 
Information Line for up-to-date information on this meeting. A notice 
in the Federal Register about last minute modifications that impact a 
previously announced advisory committee meeting cannot always be 
published quickly enough to provide timely notice. Therefore, you 
should always check the agency's Web site and call the appropriate 
advisory committee hot line/phone line to learn about possible 
modifications before coming to the meeting.
    Agenda: On September 5, 2007, the committee will discuss new drug 
application (NDA) 22-145, raltegravir potassium, integrase inhibitor 
400 milligram tablets, Merck & Co., Inc., for the treatment of Human 
Immunodeficiency Virus-1 (HIV-1) infection in combination with other

[[Page 38087]]

antiretroviral agents in treatment-experienced patients with evidence 
of HIV-1 replication despite ongoing antiretroviral therapy. On 
September 6, 2007, the meeting will be closed to permit discussion and 
review of trade secret and/or confidential information.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at http://www.fda.gov/ohrms/dockets/ac/acmenu.htm, click on 
the year 2007 and scroll down to the appropriate advisory committee 
link.
    Procedure: On September 5, 2007, from 8 a.m. to 4 p.m., the meeting 
is open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Written submissions may be made to the contact person on 
or before August 21, 2007. Oral presentations from the public will be 
scheduled between approximately 1 p.m. and 2 p.m. Those desiring to 
make formal oral presentations should notify the contact person and 
submit a brief statement of the general nature of the evidence or 
arguments they wish to present, the names and addresses of proposed 
participants, and an indication of the approximate time requested to 
make their presentation on or before August 14, 2007. Time allotted for 
each presentation may be limited. If the number of registrants 
requesting to speak is greater than can be reasonably accommodated 
during the scheduled open public hearing session, FDA may conduct a 
lottery to determine the speakers for the scheduled open public hearing 
session. The contact person will notify interested persons regarding 
their request to speak by August 13, 2007.
    Closed Committee Deliberations: On September 6, 2007, from 9 a.m. 
to 1 p.m., the meeting will be closed to permit discussion and review 
of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)). 
The committee will be asked to provide feedback on a Phase 3 protocol 
in the development of a new indication.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to adisability, please contact Cicely Reese at least 
7 days in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: July 5, 2007.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E7-13560 Filed 7-11-07; 8:45 am]
BILLING CODE 4160-01-S